header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-28408
Fish name: as3Tg
Genotype: as3Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by as3Tg
Human Disease Conditions Citations
fatty liver disease chemical treatment: thioacetamide Amali et al., 2006
GENE EXPRESSION
Gene expression in as3Tg
RNA expression
Expressed Gene Structure Conditions Figures
badb standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
baxa standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
casp3a standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
casp8 standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
cnr1 standard conditions Fig. S1 with image from Liu et al., 2016
cnr2 standard conditions Fig. S1 with image from Liu et al., 2016
cp standard conditions Fig. 2 with imageFig. 7 with imageFig. S2 with image from Lu et al., 2013
hamp standard conditions Fig. 4 with image from Gibert et al., 2011
hhex standard conditions Fig. 2 with imageFig. 7 with imageFig. S2 with image from Lu et al., 2013
hjv standard conditions Fig. 4 with image from Gibert et al., 2011
mapk8b standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
mapk14a standard conditions Fig. 2 from Amali et al., 2006
chemical treatment: thioacetamide Fig. 2 from Amali et al., 2006
srebf1 standard conditions Fig. S6 from Liu et al., 2016
srebf2 standard conditions Fig. S6 from Liu et al., 2016
tfa standard conditions Fig. 4 with image from Gibert et al., 2011
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab3-h3 standard conditions Fig. 5 with image from Lin et al., 2014
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 21 figures with image from 11 publications
chemical treatment: prostaglandin E2 Fig. 7 with image from Nissim et al., 2016
Fig. 1 with imageFig. 3 with image from Nissim et al., 2014
PHENOTYPE
Phenotype in as3Tg
Phenotype Conditions Figures
hepatocyte increased amount, abnormal chemical treatment: cannabinoid receptor agonist Fig. S1 with image from Liu et al., 2016
liver EGFP expression decreased distribution, abnormal chemical treatment: indometacin Fig. 1 with image from Nissim et al., 2014
liver EGFP expression decreased distribution, abnormal chemical treatment: indometacin Fig. 3 with image from Nissim et al., 2014
liver decreased size, abnormal chemical treatment: indometacin Fig. 3 with image from Nissim et al., 2014
liver decreased size, abnormal chemical treatment: indometacin Fig. 1 with image from Nissim et al., 2014
liver decreased size, abnormal chemical treatment: 1-(3'-{1-[2-(morpholin-4-yl)ethyl]pyrazol-3-yl}[1,1'-biphenyl]-3-yl)ethan-1-one Fig. 7 with image from Nissim et al., 2016
liver EGFP expression increased distribution, abnormal chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
liver EGFP expression increased distribution, abnormal chemical treatment: prostaglandin E2 Fig. 3 with image from Nissim et al., 2014
liver increased size, abnormal chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
liver increased size, abnormal chemical treatment: prostaglandin E2 Fig. 3 with image from Nissim et al., 2014
liver cell decreased amount, abnormal chemical treatment: indometacin Fig. 1 with image from Nissim et al., 2014
liver cell increased amount, abnormal chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014

CITATIONS  (27)